Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

Background/Aims Adherence to medication and maintained virologic response (MVR) are related to the risk of adverse clinical outcomes. This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatit...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2021-05, Vol.66 (5), p.1739-1750
Main Authors: Shin, Jung Woo, Jeong, Joonho, Jung, Seok Won, Lee, Seung Bum, Park, Bo Ryung, Kim, Min-Ju, Park, Eun Ji, Park, Neung Hwa
Format: Article
Language:English
Subjects:
Analysis
Antigens
Antiretroviral drugs
Antiviral drugs
Biochemistry
Cancer
Care and treatment
Clinical outcomes
Deoxyribonucleic acid
DNA
Entecavir
Gastroenterology
Genetic testing
Hepatitis B
Hepatology
Hospitals
Liver cancer
Medical colleges
Medical records
Medicine
Medicine & Public Health
Oncology
Original Article
Patients
Tenofovir
Transplant Surgery
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims Adherence to medication and maintained virologic response (MVR) are related to the risk of adverse clinical outcomes. This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatitis B (CHB) patients stratified according to adherence to medication and MVR. Methods A total of 1794 treatment-naive CHB patients treated with ETV ( n  = 894) or TDF ( n  = 900) for > 1 year were identified. Results Adherence rates were significantly higher in the TDF than in the ETV (93.4% vs. 89.1%, respectively; P  
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-020-06375-3